A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer

OBJECTIVE: We aimed to evaluate the effectiveness of an mEOX (modified epirubicin, oxaliplatin plus capecitabine) regimen as second line therapy after failure of mDCF (modified docetaxel, cisplatin plus fluorouracil). METHODS: Gastic cancer patients for whom first-line therapy was unsuccessful and w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozkaya, Yakup, Özdemir, Nuriye Yıldırım, Yazıcı, Ozan, Demirci, Nebi Serkan, Kurtipek, Alican, Erdem, Gökmen Umut, Ergün, Yakup, Zengin, Nurullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844632/
https://www.ncbi.nlm.nih.gov/pubmed/29374414
http://dx.doi.org/10.22034/APJCP.2018.19.1.283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844632/
https://www.ncbi.nlm.nih.gov/pubmed/29374414
http://dx.doi.org/10.22034/APJCP.2018.19.1.283

Ejemplares similares